eric
02-20-2008, 06:14 AM
http://www.newsrx.com/library/topics/Breast-Cancer/186.html
The researchers concluded: "The combination of trastuzumab and the mTOR inhibitor RAD001 also slowed breast cancer cell growth in vitro (http://www.newsrx.com/library/topics/Breast-Cancer/186.html#) and in vivo (http://www.newsrx.com/library/topics/Breast-Cancer/186.html#) Combining trastuzumab with inhibitors of the Akt/mTOR pathway is a clinically applicable strategy and combinations of trastuzumab with triciribine or RAD001 are promising regimens for rescue of trastuzumab resistance caused by PTEN loss."
The researchers concluded: "The combination of trastuzumab and the mTOR inhibitor RAD001 also slowed breast cancer cell growth in vitro (http://www.newsrx.com/library/topics/Breast-Cancer/186.html#) and in vivo (http://www.newsrx.com/library/topics/Breast-Cancer/186.html#) Combining trastuzumab with inhibitors of the Akt/mTOR pathway is a clinically applicable strategy and combinations of trastuzumab with triciribine or RAD001 are promising regimens for rescue of trastuzumab resistance caused by PTEN loss."